Stay informed with the latest insights and perspectives from Withum.
The AICPA’s Employee Benefit Plans Expert Panel was formed to protect the public interest and agree on key plan issues by leveraging the knowledge of leaders in the employee benefit plan industry. Nadia’s deep expertise makes her a valuable asset to help further the panel’s mission as Chair of the group. Nadia has more than…
For health system and digital health leaders, enterprise value is often assessed through familiar financial lenses, such as revenue growth, EBITDA margins, and scale potential. These metrics remain important. However, in digital health, they rarely explain why value persists, where risk accumulates, or how short-term performance translates into long-term enterprise value. This disconnect exists because…
Few financial disciplines separate well-run businesses from struggling ones as clearly as a clean boundary between business and personal expenses. It is easy to dismiss this practice as administrative housekeeping. In reality, the failure to keep the two separate quietly undermines nearly every financial decision an owner makes. When business and personal spending are commingled,…
Real estate professionals and investors will inevitably encounter situations where selling a property becomes necessary. The classification and accounting treatment can significantly impact their financial statements. ASC 360, under US GAAP, requires that long-lived assets be classified as held for sale in the period in which all of the held-for-sale criteria are met. Once all…
When people think of research and development (R&D), they often picture tech startups or pharmaceutical labs; rarely does the conversation turn to oil and gas. Yet in hubs like Houston, the energy industry is one of the most innovation-driven sectors in the United States and a prime candidate for the federal R&D Tax Credit under…
The Orphan Drug Credit (ODC) is a powerful federal tax incentive designed to encourage the development of treatments for rare diseases, generally defined as conditions affecting fewer than 200,000 individuals in the United States. For biotechnology and pharmaceutical companies advancing therapies through clinical trials, the ODC can deliver a significantly enhanced tax benefit compared to…
